{"gene":"EXTL2","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1999,"finding":"EXTL2 encodes an alpha1,4-N-acetylhexosaminyltransferase that transfers both GalNAc and GlcNAc to the common glycosaminoglycan-protein linkage region tetrasaccharide (GlcAbeta1-3Galbeta1-3Galbeta1-4Xylbeta1-O-Ser), establishing it as the key enzyme for initiation of heparin/heparan sulfate chain synthesis and for determining chain type (HS vs CS/DS).","method":"Protein purification from human sarcoma cell culture medium, peptide sequencing, recombinant expression of soluble enzyme, in vitro transferase assay with UDP-[3H]GalNAc and UDP-[3H]GlcNAc, heparitinase I sensitivity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic reconstitution with purified/recombinant protein, multiple substrates tested, product identity confirmed by glycosidase sensitivity, replicated by subsequent structural work","pmids":["10318803"],"is_preprint":false},{"year":2003,"finding":"Crystal structures of mouse EXTL2 catalytic domain in apo form, with donor substrates UDP-GlcNAc and UDP-GalNAc, and as a ternary complex with UDP and acceptor substrate analog revealed three active-site residues (Asn-243, Asp-246, Arg-293) critical for catalysis; mutation of these residues greatly decreases activity. An interaction between the beta-phosphate of the UDP leaving group and the acceptor hydroxyl was identified as potentially functional in catalysis.","method":"X-ray crystallography of apo, donor-bound, and ternary complex structures; site-directed mutagenesis with activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures at multiple ligand states combined with mutagenesis confirming catalytic residues; rigorous multi-method single study","pmids":["12562774"],"is_preprint":false},{"year":2013,"finding":"EXTL2 terminates GAG chain elongation by specifically transferring a GlcNAc residue to the tetrasaccharide linkage region when it is phosphorylated at xylose-2-O by xylose kinase 1 (FAM20B), generating a phosphorylated pentasaccharide (GlcNAcalpha1-4GlcUAbeta1-3Galbeta1-3Galbeta1-4Xyl(2-O-phosphate)) that cannot serve as an acceptor for HS or CS polymerases, thereby suppressing GAG biosynthesis.","method":"EXTL2 knockout mice, oligosaccharide isolation from mouse liver, glycosidase digestion and 1H NMR structural analysis, in vitro transferase assay with phosphorylated acceptor substrates, GAG quantification in KO vs WT mice","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic assay with defined phosphorylated substrate, structural characterization of product by NMR, KO mouse validation with quantitative GAG measurement; multiple orthogonal methods","pmids":["23395820"],"is_preprint":false},{"year":2013,"finding":"EXTL2-mediated regulation of GAG biosynthesis is required for normal liver regeneration after CCl4-induced injury; EXTL2-knockout mice show impaired hepatocyte proliferation and reduced HGF-mediated signaling specifically due to altered GAG synthesis in hepatic stellate cells.","method":"EXTL2-knockout mice, CCl4-induced liver failure model, liver/body weight ratio, hepatocyte proliferation assays, HGF signaling pathway analysis","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse with defined cellular phenotype (proliferation, signaling) and pathway placement (HGF), single lab with multiple readouts","pmids":["23734945"],"is_preprint":false},{"year":2013,"finding":"Under chronic kidney disease conditions, EXTL2-knockout mice show enhanced matrix mineralization in vascular smooth muscle cells (VSMCs) in aortic rings; this is linked to altered GAG biosynthesis affecting bone morphogenetic protein (BMP) signaling and enhanced differentiation of VSMCs into osteoblasts.","method":"EXTL2-knockout mice, 5/6th nephrectomy + high-phosphate diet model, aortic ring mineralization assay, BMP signaling analysis","journal":"Matrix biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse with defined cellular phenotype and pathway placement (BMP signaling), single lab","pmids":["24176719"],"is_preprint":false},{"year":2015,"finding":"siRNA-mediated knockdown of EXTL2 in HEK293 cells results in increased heparan sulfate chain length, while overexpression had little or no effect on chain length; in vitro, recombinant EXTL2 showed weak GalNAc-transferase activity on HS precursor molecules but stronger GlcNAc-transferase activity related to HS chain elongation.","method":"siRNA knockdown and overexpression in HEK293 cells, HS chain length analysis, in vitro transferase assay with oligosaccharide acceptors","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro transferase assay combined with cell-based knockdown/overexpression and chain length measurement; single lab, two orthogonal methods","pmids":["25829497"],"is_preprint":false},{"year":2006,"finding":"Isothermal titration calorimetry demonstrated that human EXTL2 uses a two-step mechanism to regulate specific binding of N-acetylhexosamines (GlcNAc and GalNAc), providing thermodynamic parameters (stoichiometry, affinity, ΔG, ΔH, ΔS) for donor substrate binding; EXTL2 does not bind glucose or galactose.","method":"Isothermal titration calorimetry (ITC) with purified human EXTL2","journal":"Methods in enzymology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — rigorous biophysical method characterizing binding mechanism, single lab, single method","pmids":["17113856"],"is_preprint":false},{"year":2017,"finding":"QM(DFT)/MM calculations and molecular dynamics simulations of wild-type EXTL2 and mutants at Arg293 and Asp246 clarified the catalytic roles of these residues: Arg293 facilitates binding and catalysis (not merely contradicting an oxocarbenium mechanism), Asp246 acts on the beta-face and controls regioselectivity such that an Asp246Glu mutant is predicted unable to catalyze alpha-1,4 transfer, and Leu213 contributes to substrate specificity at different catalytic stages.","method":"QM(DFT)/MM calculations, molecular dynamics simulations, site-directed mutagenesis interpretation","journal":"Organic & biomolecular chemistry","confidence":"Low","confidence_rationale":"Tier 4 / Weak — computational study with mutagenesis interpretation; Asp246Glu prediction not experimentally confirmed in this paper","pmids":["28905966"],"is_preprint":false},{"year":2020,"finding":"EXTL2 deficiency in mice leads to excessive CSPG deposition in demyelinating spinal cord lesions; EXTL2-/- mice show exacerbated axonal damage, myelin disruption, and increased microglia/macrophage infiltration. Activated bone marrow-derived macrophages from EXTL2-/- mice overproduce TNFalpha and matrix metalloproteinases (MMPs).","method":"EXTL2-/- mice, spinal cord demyelination model (lysolecithin), histological analysis, bone marrow-derived macrophage culture, TNFalpha and MMP assays, oligodendrocyte precursor cell and neuron culture with conditioned media","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse with defined cellular phenotype and multiple downstream readouts (CSPG deposition, macrophage activation, TNFalpha, MMPs); single lab, multiple orthogonal methods","pmids":["32703234"],"is_preprint":false},{"year":2020,"finding":"GAGs produced in the absence of EXTL2 act as damage-associated molecular pattern molecules (DAMPs) that signal through Toll-like receptor 4 (TLR4), activating NF-kappaB-mediated transcription of inflammatory and tumor-promoting cytokines, thereby promoting non-alcoholic steatohepatitis and hepatocellular carcinoma in diet-induced obese/insulin-resistant mice.","method":"EXTL2-knockout mice, dietary obesity/insulin-resistance model, TLR4 signaling assays, NF-kappaB transcriptional activation assays, cytokine measurements","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse with pathway placement (TLR4/NF-kappaB), multiple functional readouts; single lab","pmids":["32347583"],"is_preprint":false},{"year":2022,"finding":"In gastric cancer cells, EXTL2 knockout increases HS chain levels and upregulates Syndecan-4 expression on the cell surface, promoting greater cellular motility and invasion and impairing activation of Ephrin type-A 4 (EphA4) receptor tyrosine kinase; EXTL2 functions as a negative regulator of HS biosynthesis, influencing the HS/CS ratio and the cancer cell glycoproteome.","method":"CRISPR/Cas9 KO of EXTL2 in gastric cancer cells, GAG chain analysis, proteoglycan expression profiling, cell motility and invasion assays, EphA4 activation assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined cellular phenotypes and signaling readout (EphA4), single lab, multiple orthogonal methods","pmids":["36181793"],"is_preprint":false},{"year":2009,"finding":"shRNA-mediated knockdown of EXTL2 in fibroblasts reduces endogenous EXTL2 mRNA by up to 68% and decreases GAG synthesis by up to 50%, and reduces lysosomal GAG levels in MPS IIIA and MPS I fibroblasts.","method":"shRNA knockdown in fibroblasts, reporter gene assay, RT-PCR, GAG synthesis measurement, lysosomal GAG quantification","journal":"European journal of human genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — gene silencing with functional readout (GAG synthesis) but no molecular mechanism beyond confirming EXTL2 contribution to GAG biosynthesis; single lab, single method type","pmids":["19690583"],"is_preprint":false}],"current_model":"EXTL2 is an alpha1,4-N-acetylhexosaminyltransferase that transfers GlcNAc (and GalNAc) to the common GAG-protein linkage tetrasaccharide, with its crystal structure revealing catalytic residues Asn-243, Asp-246, and Arg-293; it preferentially acts on xylose-2-O-phosphorylated linkage tetrasaccharides (generated by FAM20B kinase) to terminate GAG chain elongation via a phosphorylated pentasaccharide intermediate that cannot be extended by HS or CS polymerases, thereby functioning as a negative regulator of overall GAG biosynthesis with downstream consequences for HGF and BMP signaling in liver regeneration, TLR4-mediated inflammation, CSPG-dependent neuroinflammation, and cancer cell motility."},"narrative":{"mechanistic_narrative":"EXTL2 is an alpha1,4-N-acetylhexosaminyltransferase that acts at the common glycosaminoglycan (GAG)-protein linkage tetrasaccharide and serves as a negative regulator of overall GAG biosynthesis [PMID:10318803, PMID:23395820]. Although originally characterized as an enzyme that transfers both GalNAc and GlcNAc to the linkage region tetrasaccharide [PMID:10318803], its physiologically decisive activity is the transfer of GlcNAc to the linkage tetrasaccharide when xylose is 2-O-phosphorylated by the kinase FAM20B, generating a phosphorylated pentasaccharide that cannot be elongated by HS or CS polymerases and thereby terminating chain extension [PMID:23395820]. Crystal structures in apo, donor-bound (UDP-GlcNAc/UDP-GalNAc), and ternary states identified Asn-243, Asp-246, and Arg-293 as catalytic residues required for activity, with Asp-246 governing regioselectivity for alpha-1,4 transfer [PMID:12562774]. Consistent with a chain-terminating role, loss of EXTL2 in cells and mice increases HS chain length and total GAG output and shifts the HS/CS ratio [PMID:25829497, PMID:36181793]. Through its control of GAG quantity and structure, EXTL2 modulates multiple downstream signaling outcomes: HGF-dependent hepatocyte proliferation during liver regeneration [PMID:23734945], BMP signaling and vascular smooth muscle mineralization under chronic kidney disease [PMID:24176719], TLR4/NF-kappaB inflammatory signaling driving steatohepatitis and hepatocellular carcinoma [PMID:32347583], CSPG-associated neuroinflammation and macrophage activation in demyelinating lesions [PMID:32703234], and Syndecan-4/EphA4-linked gastric cancer cell motility and invasion [PMID:36181793].","teleology":[{"year":1999,"claim":"Established the enzymatic identity of EXTL2 as an alpha1,4-N-acetylhexosaminyltransferase acting on the GAG-protein linkage tetrasaccharide, defining its biochemical entry point into GAG chain biosynthesis.","evidence":"Protein purification from human sarcoma medium, recombinant soluble enzyme, in vitro transferase assays with UDP-[3H]GalNAc/GlcNAc, glycosidase sensitivity","pmids":["10318803"],"confidence":"High","gaps":["Did not establish whether the dominant in vivo role is initiation or termination of chains","Substrate phosphorylation requirement not yet recognized"]},{"year":2003,"claim":"Resolved the structural basis of catalysis, pinpointing the active-site residues and donor/acceptor geometry that enable hexosamine transfer.","evidence":"X-ray crystallography of apo, donor-bound, and ternary complexes with site-directed mutagenesis and activity assays in mouse EXTL2","pmids":["12562774"],"confidence":"High","gaps":["Catalytic mechanism (e.g. oxocarbenium vs alternative) not fully resolved","Structure does not address phosphorylated acceptor recognition"]},{"year":2006,"claim":"Characterized the thermodynamics and specificity of donor binding, showing a two-step binding mechanism selective for N-acetylhexosamines.","evidence":"Isothermal titration calorimetry with purified human EXTL2","pmids":["17113856"],"confidence":"Medium","gaps":["Single biophysical method, single lab","Does not connect binding mechanism to cellular regulation of GAG output"]},{"year":2009,"claim":"Provided early cellular evidence that EXTL2 contributes to GAG synthesis, linking it to lysosomal GAG content in mucopolysaccharidosis fibroblasts.","evidence":"shRNA knockdown in MPS IIIA/MPS I fibroblasts with RT-PCR and GAG synthesis/lysosomal GAG quantification","pmids":["19690583"],"confidence":"Low","gaps":["Single method type, no molecular mechanism beyond GAG contribution","Direction of regulation (initiation vs termination) not addressed"]},{"year":2013,"claim":"Reframed EXTL2 as a negative regulator of GAG biosynthesis by showing it terminates chain elongation through GlcNAc transfer to FAM20B-phosphorylated linkage tetrasaccharide, generating a non-extendable pentasaccharide.","evidence":"EXTL2 KO mice, oligosaccharide isolation from liver, NMR structural analysis, in vitro transferase assays with phosphorylated acceptors, GAG quantification","pmids":["23395820"],"confidence":"High","gaps":["Quantitative contribution of termination vs initiation across tissues not defined","Regulation of FAM20B/EXTL2 coupling unknown"]},{"year":2013,"claim":"Connected EXTL2-controlled GAG synthesis to organ physiology, showing it is required for HGF-driven hepatocyte proliferation during liver regeneration.","evidence":"EXTL2 KO mice, CCl4 liver injury model, hepatocyte proliferation and HGF signaling analysis","pmids":["23734945"],"confidence":"Medium","gaps":["Single lab","Direct molecular link between altered GAG structure and HGF receptor engagement not resolved"]},{"year":2013,"claim":"Extended the physiological reach of EXTL2 to vascular pathology, implicating its GAG regulation in BMP signaling and VSMC osteoblastic differentiation under chronic kidney disease.","evidence":"EXTL2 KO mice, 5/6 nephrectomy + high-phosphate diet, aortic ring mineralization and BMP signaling analysis","pmids":["24176719"],"confidence":"Medium","gaps":["Mechanism by which altered GAGs modulate BMP signaling not defined","Single lab"]},{"year":2015,"claim":"Confirmed in human cells that EXTL2 limits HS chain length, with knockdown increasing chain length while overexpression had little effect, consistent with a chain-terminating regulatory role.","evidence":"siRNA knockdown and overexpression in HEK293 cells, HS chain length analysis, in vitro transferase assays","pmids":["25829497"],"confidence":"Medium","gaps":["Asymmetry between knockdown and overexpression effects not mechanistically explained","Single lab"]},{"year":2017,"claim":"Used computation to refine the catalytic roles of active-site residues, attributing regioselectivity to Asp246 and binding/catalysis support to Arg293.","evidence":"QM(DFT)/MM calculations and molecular dynamics with mutagenesis interpretation","pmids":["28905966"],"confidence":"Low","gaps":["Asp246Glu loss-of-alpha1,4-transfer prediction not experimentally confirmed in this study","Computational interpretation only"]},{"year":2020,"claim":"Demonstrated that EXTL2 loss drives neuroinflammation via excessive CSPG deposition and macrophage overproduction of TNFalpha and MMPs in demyelinating lesions.","evidence":"EXTL2-/- mice, lysolecithin demyelination model, histology, bone marrow-derived macrophage culture with TNFalpha/MMP assays","pmids":["32703234"],"confidence":"Medium","gaps":["Receptor/pathway linking CSPG excess to macrophage activation not fully defined here","Single lab"]},{"year":2020,"claim":"Identified a signaling mechanism for EXTL2-regulated GAGs, showing that GAGs accumulating in its absence act as DAMPs engaging TLR4/NF-kappaB to promote steatohepatitis and hepatocellular carcinoma.","evidence":"EXTL2 KO mice, diet-induced obesity/insulin-resistance model, TLR4 and NF-kappaB activation assays, cytokine measurements","pmids":["32347583"],"confidence":"Medium","gaps":["Structural features of the GAG DAMP recognized by TLR4 not defined","Single lab"]},{"year":2022,"claim":"Showed in cancer cells that EXTL2 loss raises HS levels, upregulates Syndecan-4, impairs EphA4 activation, and enhances motility and invasion, linking GAG dysregulation to the cancer cell glycoproteome.","evidence":"CRISPR/Cas9 KO in gastric cancer cells, GAG and proteoglycan profiling, motility/invasion and EphA4 activation assays","pmids":["36181793"],"confidence":"Medium","gaps":["Causal chain from HS increase to EphA4 impairment not mechanistically resolved","Single lab, single cancer model"]},{"year":null,"claim":"How EXTL2 activity is regulated and coordinated with FAM20B phosphorylation across tissues, and how specific GAG structural changes are decoded by distinct receptors (HGF, BMP, TLR4, EphA4), remains unresolved.","evidence":"No timeline discovery directly addresses upstream regulation of EXTL2 or the structural code linking its GAG products to specific receptor outcomes","pmids":[],"confidence":"Low","gaps":["Upstream regulators of EXTL2 expression/activity unknown","Unified structural model linking GAG length/composition to receptor selectivity absent","Tissue-specific balance of initiation vs termination not quantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,2,5]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,5,10]}],"localization":[],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[0,2]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,2]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,4,9,10]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[8,9]}],"complexes":[],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9UBQ6","full_name":"Exostosin-like 2","aliases":["Alpha-1,4-N-acetylhexosaminyltransferase EXTL2","Alpha-GalNAcT EXTL2","EXT-related protein 2","Glucuronyl-galactosyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase"],"length_aa":330,"mass_kda":37.5,"function":"Glycosyltransferase required for the biosynthesis of heparan-sulfate and responsible for the alternating addition of beta-1-4-linked glucuronic acid (GlcA) and alpha-1-4-linked N-acetylglucosamine (GlcNAc) units to nascent heparan sulfate chains","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q9UBQ6/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/EXTL2","classification":"Not Classified","n_dependent_lines":58,"n_total_lines":1208,"dependency_fraction":0.048013245033112585},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/EXTL2","total_profiled":1310},"omim":[{"mim_id":"608177","title":"EXOSTOSIN GLYCOSYLTRANSFERASE 1; EXT1","url":"https://www.omim.org/entry/608177"},{"mim_id":"605744","title":"EXOSTOSIN-LIKE GLYCOSYLTRANSFERASE 3; EXTL3","url":"https://www.omim.org/entry/605744"},{"mim_id":"602411","title":"EXOSTOSIN-LIKE GLYCOSYLTRANSFERASE 2; EXTL2","url":"https://www.omim.org/entry/602411"},{"mim_id":"601738","title":"EXOSTOSIN-LIKE GLYCOSYLTRANSFERASE 1; EXTL1","url":"https://www.omim.org/entry/601738"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/EXTL2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q9UBQ6","domains":[{"cath_id":"3.90.550.10","chopping":"66-317","consensus_level":"high","plddt":96.01,"start":66,"end":317}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UBQ6","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UBQ6-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UBQ6-F1-predicted_aligned_error_v6.png","plddt_mean":88.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=EXTL2","jax_strain_url":"https://www.jax.org/strain/search?query=EXTL2"},"sequence":{"accession":"Q9UBQ6","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UBQ6.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UBQ6/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UBQ6"}},"corpus_meta":[{"pmid":"10318803","id":"PMC_10318803","title":"The tumor suppressor EXT-like gene EXTL2 encodes an alpha1, 4-N-acetylhexosaminyltransferase that transfers N-acetylgalactosamine and N-acetylglucosamine to the common glycosaminoglycan-protein linkage region. The key enzyme for the chain initiation of heparan sulfate.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10318803","citation_count":155,"is_preprint":false},{"pmid":"12562774","id":"PMC_12562774","title":"Crystal structure of an alpha 1,4-N-acetylhexosaminyltransferase (EXTL2), a member of the exostosin gene family involved in heparan sulfate biosynthesis.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12562774","citation_count":82,"is_preprint":false},{"pmid":"9450183","id":"PMC_9450183","title":"Identification and characterization of a novel member of the EXT gene family, EXTL2.","date":"1997","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/9450183","citation_count":81,"is_preprint":false},{"pmid":"23395820","id":"PMC_23395820","title":"EXTL2, a member of the EXT family of tumor suppressors, controls glycosaminoglycan biosynthesis in a xylose kinase-dependent manner.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23395820","citation_count":70,"is_preprint":false},{"pmid":"19690583","id":"PMC_19690583","title":"Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses.","date":"2009","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/19690583","citation_count":38,"is_preprint":false},{"pmid":"26347037","id":"PMC_26347037","title":"EXTL2 and EXTL3 inhibition with siRNAs as a promising substrate reduction therapy for Sanfilippo C syndrome.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26347037","citation_count":23,"is_preprint":false},{"pmid":"23734945","id":"PMC_23734945","title":"Roles of EXTL2, a member of the EXT family of tumour suppressors, in liver injury and regeneration processes.","date":"2013","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/23734945","citation_count":20,"is_preprint":false},{"pmid":"32347583","id":"PMC_32347583","title":"Aberrant glycosaminoglycan biosynthesis by tumor suppressor EXTL2 deficiency promotes liver inflammation and tumorigenesis through Toll-like 4 receptor signaling.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32347583","citation_count":18,"is_preprint":false},{"pmid":"32703234","id":"PMC_32703234","title":"The glycosyltransferase EXTL2 promotes proteoglycan deposition and injurious neuroinflammation following demyelination.","date":"2020","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/32703234","citation_count":18,"is_preprint":false},{"pmid":"24176719","id":"PMC_24176719","title":"EXTL2 controls liver regeneration and aortic calcification through xylose kinase-dependent regulation of glycosaminoglycan biosynthesis.","date":"2013","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/24176719","citation_count":15,"is_preprint":false},{"pmid":"36181793","id":"PMC_36181793","title":"Glycosyltransferases EXTL2 and EXTL3 cellular balance dictates heparan sulfate biosynthesis and shapes gastric cancer cell motility and invasion.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36181793","citation_count":12,"is_preprint":false},{"pmid":"25829497","id":"PMC_25829497","title":"Reduced Expression of EXTL2, a Member of the Exostosin (EXT) Family of Glycosyltransferases, in Human Embryonic Kidney 293 Cells Results in Longer Heparan Sulfate Chains.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25829497","citation_count":11,"is_preprint":false},{"pmid":"28905966","id":"PMC_28905966","title":"Computational insights into active site shaping for substrate specificity and reaction regioselectivity in the EXTL2 retaining glycosyltransferase.","date":"2017","source":"Organic & biomolecular chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28905966","citation_count":10,"is_preprint":false},{"pmid":"32517548","id":"PMC_32517548","title":"Altered Expression of Aggrecan, FAM20B, B3GALT6, and EXTL2 in Patients with Osteoarthritis and Kashin-Beck Disease.","date":"2020","source":"Cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/32517548","citation_count":8,"is_preprint":false},{"pmid":"10965119","id":"PMC_10965119","title":"Characterization and genomic localization of the mouse Extl2 gene.","date":"2000","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10965119","citation_count":6,"is_preprint":false},{"pmid":"17113856","id":"PMC_17113856","title":"Characterization of specific donor binding to alpha1,4-N-acetylhexosaminyltransferase EXTL2 using isothermal titration calorimetry.","date":"2006","source":"Methods in enzymology","url":"https://pubmed.ncbi.nlm.nih.gov/17113856","citation_count":5,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":10165,"output_tokens":3382,"usd":0.040613,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10962,"output_tokens":3924,"usd":0.076455,"stage2_stop_reason":"end_turn"},"total_usd":0.117068,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"EXTL2 encodes an alpha1,4-N-acetylhexosaminyltransferase that transfers both GalNAc and GlcNAc to the common glycosaminoglycan-protein linkage region tetrasaccharide (GlcAbeta1-3Galbeta1-3Galbeta1-4Xylbeta1-O-Ser), establishing it as the key enzyme for initiation of heparin/heparan sulfate chain synthesis and for determining chain type (HS vs CS/DS).\",\n      \"method\": \"Protein purification from human sarcoma cell culture medium, peptide sequencing, recombinant expression of soluble enzyme, in vitro transferase assay with UDP-[3H]GalNAc and UDP-[3H]GlcNAc, heparitinase I sensitivity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic reconstitution with purified/recombinant protein, multiple substrates tested, product identity confirmed by glycosidase sensitivity, replicated by subsequent structural work\",\n      \"pmids\": [\"10318803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Crystal structures of mouse EXTL2 catalytic domain in apo form, with donor substrates UDP-GlcNAc and UDP-GalNAc, and as a ternary complex with UDP and acceptor substrate analog revealed three active-site residues (Asn-243, Asp-246, Arg-293) critical for catalysis; mutation of these residues greatly decreases activity. An interaction between the beta-phosphate of the UDP leaving group and the acceptor hydroxyl was identified as potentially functional in catalysis.\",\n      \"method\": \"X-ray crystallography of apo, donor-bound, and ternary complex structures; site-directed mutagenesis with activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures at multiple ligand states combined with mutagenesis confirming catalytic residues; rigorous multi-method single study\",\n      \"pmids\": [\"12562774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"EXTL2 terminates GAG chain elongation by specifically transferring a GlcNAc residue to the tetrasaccharide linkage region when it is phosphorylated at xylose-2-O by xylose kinase 1 (FAM20B), generating a phosphorylated pentasaccharide (GlcNAcalpha1-4GlcUAbeta1-3Galbeta1-3Galbeta1-4Xyl(2-O-phosphate)) that cannot serve as an acceptor for HS or CS polymerases, thereby suppressing GAG biosynthesis.\",\n      \"method\": \"EXTL2 knockout mice, oligosaccharide isolation from mouse liver, glycosidase digestion and 1H NMR structural analysis, in vitro transferase assay with phosphorylated acceptor substrates, GAG quantification in KO vs WT mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic assay with defined phosphorylated substrate, structural characterization of product by NMR, KO mouse validation with quantitative GAG measurement; multiple orthogonal methods\",\n      \"pmids\": [\"23395820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"EXTL2-mediated regulation of GAG biosynthesis is required for normal liver regeneration after CCl4-induced injury; EXTL2-knockout mice show impaired hepatocyte proliferation and reduced HGF-mediated signaling specifically due to altered GAG synthesis in hepatic stellate cells.\",\n      \"method\": \"EXTL2-knockout mice, CCl4-induced liver failure model, liver/body weight ratio, hepatocyte proliferation assays, HGF signaling pathway analysis\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with defined cellular phenotype (proliferation, signaling) and pathway placement (HGF), single lab with multiple readouts\",\n      \"pmids\": [\"23734945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Under chronic kidney disease conditions, EXTL2-knockout mice show enhanced matrix mineralization in vascular smooth muscle cells (VSMCs) in aortic rings; this is linked to altered GAG biosynthesis affecting bone morphogenetic protein (BMP) signaling and enhanced differentiation of VSMCs into osteoblasts.\",\n      \"method\": \"EXTL2-knockout mice, 5/6th nephrectomy + high-phosphate diet model, aortic ring mineralization assay, BMP signaling analysis\",\n      \"journal\": \"Matrix biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with defined cellular phenotype and pathway placement (BMP signaling), single lab\",\n      \"pmids\": [\"24176719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"siRNA-mediated knockdown of EXTL2 in HEK293 cells results in increased heparan sulfate chain length, while overexpression had little or no effect on chain length; in vitro, recombinant EXTL2 showed weak GalNAc-transferase activity on HS precursor molecules but stronger GlcNAc-transferase activity related to HS chain elongation.\",\n      \"method\": \"siRNA knockdown and overexpression in HEK293 cells, HS chain length analysis, in vitro transferase assay with oligosaccharide acceptors\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro transferase assay combined with cell-based knockdown/overexpression and chain length measurement; single lab, two orthogonal methods\",\n      \"pmids\": [\"25829497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Isothermal titration calorimetry demonstrated that human EXTL2 uses a two-step mechanism to regulate specific binding of N-acetylhexosamines (GlcNAc and GalNAc), providing thermodynamic parameters (stoichiometry, affinity, ΔG, ΔH, ΔS) for donor substrate binding; EXTL2 does not bind glucose or galactose.\",\n      \"method\": \"Isothermal titration calorimetry (ITC) with purified human EXTL2\",\n      \"journal\": \"Methods in enzymology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — rigorous biophysical method characterizing binding mechanism, single lab, single method\",\n      \"pmids\": [\"17113856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"QM(DFT)/MM calculations and molecular dynamics simulations of wild-type EXTL2 and mutants at Arg293 and Asp246 clarified the catalytic roles of these residues: Arg293 facilitates binding and catalysis (not merely contradicting an oxocarbenium mechanism), Asp246 acts on the beta-face and controls regioselectivity such that an Asp246Glu mutant is predicted unable to catalyze alpha-1,4 transfer, and Leu213 contributes to substrate specificity at different catalytic stages.\",\n      \"method\": \"QM(DFT)/MM calculations, molecular dynamics simulations, site-directed mutagenesis interpretation\",\n      \"journal\": \"Organic & biomolecular chemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — computational study with mutagenesis interpretation; Asp246Glu prediction not experimentally confirmed in this paper\",\n      \"pmids\": [\"28905966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"EXTL2 deficiency in mice leads to excessive CSPG deposition in demyelinating spinal cord lesions; EXTL2-/- mice show exacerbated axonal damage, myelin disruption, and increased microglia/macrophage infiltration. Activated bone marrow-derived macrophages from EXTL2-/- mice overproduce TNFalpha and matrix metalloproteinases (MMPs).\",\n      \"method\": \"EXTL2-/- mice, spinal cord demyelination model (lysolecithin), histological analysis, bone marrow-derived macrophage culture, TNFalpha and MMP assays, oligodendrocyte precursor cell and neuron culture with conditioned media\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with defined cellular phenotype and multiple downstream readouts (CSPG deposition, macrophage activation, TNFalpha, MMPs); single lab, multiple orthogonal methods\",\n      \"pmids\": [\"32703234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GAGs produced in the absence of EXTL2 act as damage-associated molecular pattern molecules (DAMPs) that signal through Toll-like receptor 4 (TLR4), activating NF-kappaB-mediated transcription of inflammatory and tumor-promoting cytokines, thereby promoting non-alcoholic steatohepatitis and hepatocellular carcinoma in diet-induced obese/insulin-resistant mice.\",\n      \"method\": \"EXTL2-knockout mice, dietary obesity/insulin-resistance model, TLR4 signaling assays, NF-kappaB transcriptional activation assays, cytokine measurements\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with pathway placement (TLR4/NF-kappaB), multiple functional readouts; single lab\",\n      \"pmids\": [\"32347583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In gastric cancer cells, EXTL2 knockout increases HS chain levels and upregulates Syndecan-4 expression on the cell surface, promoting greater cellular motility and invasion and impairing activation of Ephrin type-A 4 (EphA4) receptor tyrosine kinase; EXTL2 functions as a negative regulator of HS biosynthesis, influencing the HS/CS ratio and the cancer cell glycoproteome.\",\n      \"method\": \"CRISPR/Cas9 KO of EXTL2 in gastric cancer cells, GAG chain analysis, proteoglycan expression profiling, cell motility and invasion assays, EphA4 activation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined cellular phenotypes and signaling readout (EphA4), single lab, multiple orthogonal methods\",\n      \"pmids\": [\"36181793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"shRNA-mediated knockdown of EXTL2 in fibroblasts reduces endogenous EXTL2 mRNA by up to 68% and decreases GAG synthesis by up to 50%, and reduces lysosomal GAG levels in MPS IIIA and MPS I fibroblasts.\",\n      \"method\": \"shRNA knockdown in fibroblasts, reporter gene assay, RT-PCR, GAG synthesis measurement, lysosomal GAG quantification\",\n      \"journal\": \"European journal of human genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — gene silencing with functional readout (GAG synthesis) but no molecular mechanism beyond confirming EXTL2 contribution to GAG biosynthesis; single lab, single method type\",\n      \"pmids\": [\"19690583\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"EXTL2 is an alpha1,4-N-acetylhexosaminyltransferase that transfers GlcNAc (and GalNAc) to the common GAG-protein linkage tetrasaccharide, with its crystal structure revealing catalytic residues Asn-243, Asp-246, and Arg-293; it preferentially acts on xylose-2-O-phosphorylated linkage tetrasaccharides (generated by FAM20B kinase) to terminate GAG chain elongation via a phosphorylated pentasaccharide intermediate that cannot be extended by HS or CS polymerases, thereby functioning as a negative regulator of overall GAG biosynthesis with downstream consequences for HGF and BMP signaling in liver regeneration, TLR4-mediated inflammation, CSPG-dependent neuroinflammation, and cancer cell motility.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"EXTL2 is an alpha1,4-N-acetylhexosaminyltransferase that acts at the common glycosaminoglycan (GAG)-protein linkage tetrasaccharide and serves as a negative regulator of overall GAG biosynthesis [#0, #2]. Although originally characterized as an enzyme that transfers both GalNAc and GlcNAc to the linkage region tetrasaccharide [#0], its physiologically decisive activity is the transfer of GlcNAc to the linkage tetrasaccharide when xylose is 2-O-phosphorylated by the kinase FAM20B, generating a phosphorylated pentasaccharide that cannot be elongated by HS or CS polymerases and thereby terminating chain extension [#2]. Crystal structures in apo, donor-bound (UDP-GlcNAc/UDP-GalNAc), and ternary states identified Asn-243, Asp-246, and Arg-293 as catalytic residues required for activity, with Asp-246 governing regioselectivity for alpha-1,4 transfer [#1]. Consistent with a chain-terminating role, loss of EXTL2 in cells and mice increases HS chain length and total GAG output and shifts the HS/CS ratio [#5, #10]. Through its control of GAG quantity and structure, EXTL2 modulates multiple downstream signaling outcomes: HGF-dependent hepatocyte proliferation during liver regeneration [#3], BMP signaling and vascular smooth muscle mineralization under chronic kidney disease [#4], TLR4/NF-kappaB inflammatory signaling driving steatohepatitis and hepatocellular carcinoma [#9], CSPG-associated neuroinflammation and macrophage activation in demyelinating lesions [#8], and Syndecan-4/EphA4-linked gastric cancer cell motility and invasion [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established the enzymatic identity of EXTL2 as an alpha1,4-N-acetylhexosaminyltransferase acting on the GAG-protein linkage tetrasaccharide, defining its biochemical entry point into GAG chain biosynthesis.\",\n      \"evidence\": \"Protein purification from human sarcoma medium, recombinant soluble enzyme, in vitro transferase assays with UDP-[3H]GalNAc/GlcNAc, glycosidase sensitivity\",\n      \"pmids\": [\"10318803\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether the dominant in vivo role is initiation or termination of chains\", \"Substrate phosphorylation requirement not yet recognized\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolved the structural basis of catalysis, pinpointing the active-site residues and donor/acceptor geometry that enable hexosamine transfer.\",\n      \"evidence\": \"X-ray crystallography of apo, donor-bound, and ternary complexes with site-directed mutagenesis and activity assays in mouse EXTL2\",\n      \"pmids\": [\"12562774\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic mechanism (e.g. oxocarbenium vs alternative) not fully resolved\", \"Structure does not address phosphorylated acceptor recognition\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Characterized the thermodynamics and specificity of donor binding, showing a two-step binding mechanism selective for N-acetylhexosamines.\",\n      \"evidence\": \"Isothermal titration calorimetry with purified human EXTL2\",\n      \"pmids\": [\"17113856\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single biophysical method, single lab\", \"Does not connect binding mechanism to cellular regulation of GAG output\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Provided early cellular evidence that EXTL2 contributes to GAG synthesis, linking it to lysosomal GAG content in mucopolysaccharidosis fibroblasts.\",\n      \"evidence\": \"shRNA knockdown in MPS IIIA/MPS I fibroblasts with RT-PCR and GAG synthesis/lysosomal GAG quantification\",\n      \"pmids\": [\"19690583\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single method type, no molecular mechanism beyond GAG contribution\", \"Direction of regulation (initiation vs termination) not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Reframed EXTL2 as a negative regulator of GAG biosynthesis by showing it terminates chain elongation through GlcNAc transfer to FAM20B-phosphorylated linkage tetrasaccharide, generating a non-extendable pentasaccharide.\",\n      \"evidence\": \"EXTL2 KO mice, oligosaccharide isolation from liver, NMR structural analysis, in vitro transferase assays with phosphorylated acceptors, GAG quantification\",\n      \"pmids\": [\"23395820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of termination vs initiation across tissues not defined\", \"Regulation of FAM20B/EXTL2 coupling unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Connected EXTL2-controlled GAG synthesis to organ physiology, showing it is required for HGF-driven hepatocyte proliferation during liver regeneration.\",\n      \"evidence\": \"EXTL2 KO mice, CCl4 liver injury model, hepatocyte proliferation and HGF signaling analysis\",\n      \"pmids\": [\"23734945\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Direct molecular link between altered GAG structure and HGF receptor engagement not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended the physiological reach of EXTL2 to vascular pathology, implicating its GAG regulation in BMP signaling and VSMC osteoblastic differentiation under chronic kidney disease.\",\n      \"evidence\": \"EXTL2 KO mice, 5/6 nephrectomy + high-phosphate diet, aortic ring mineralization and BMP signaling analysis\",\n      \"pmids\": [\"24176719\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which altered GAGs modulate BMP signaling not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Confirmed in human cells that EXTL2 limits HS chain length, with knockdown increasing chain length while overexpression had little effect, consistent with a chain-terminating regulatory role.\",\n      \"evidence\": \"siRNA knockdown and overexpression in HEK293 cells, HS chain length analysis, in vitro transferase assays\",\n      \"pmids\": [\"25829497\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Asymmetry between knockdown and overexpression effects not mechanistically explained\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Used computation to refine the catalytic roles of active-site residues, attributing regioselectivity to Asp246 and binding/catalysis support to Arg293.\",\n      \"evidence\": \"QM(DFT)/MM calculations and molecular dynamics with mutagenesis interpretation\",\n      \"pmids\": [\"28905966\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Asp246Glu loss-of-alpha1,4-transfer prediction not experimentally confirmed in this study\", \"Computational interpretation only\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated that EXTL2 loss drives neuroinflammation via excessive CSPG deposition and macrophage overproduction of TNFalpha and MMPs in demyelinating lesions.\",\n      \"evidence\": \"EXTL2-/- mice, lysolecithin demyelination model, histology, bone marrow-derived macrophage culture with TNFalpha/MMP assays\",\n      \"pmids\": [\"32703234\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor/pathway linking CSPG excess to macrophage activation not fully defined here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified a signaling mechanism for EXTL2-regulated GAGs, showing that GAGs accumulating in its absence act as DAMPs engaging TLR4/NF-kappaB to promote steatohepatitis and hepatocellular carcinoma.\",\n      \"evidence\": \"EXTL2 KO mice, diet-induced obesity/insulin-resistance model, TLR4 and NF-kappaB activation assays, cytokine measurements\",\n      \"pmids\": [\"32347583\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural features of the GAG DAMP recognized by TLR4 not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed in cancer cells that EXTL2 loss raises HS levels, upregulates Syndecan-4, impairs EphA4 activation, and enhances motility and invasion, linking GAG dysregulation to the cancer cell glycoproteome.\",\n      \"evidence\": \"CRISPR/Cas9 KO in gastric cancer cells, GAG and proteoglycan profiling, motility/invasion and EphA4 activation assays\",\n      \"pmids\": [\"36181793\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal chain from HS increase to EphA4 impairment not mechanistically resolved\", \"Single lab, single cancer model\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How EXTL2 activity is regulated and coordinated with FAM20B phosphorylation across tissues, and how specific GAG structural changes are decoded by distinct receptors (HGF, BMP, TLR4, EphA4), remains unresolved.\",\n      \"evidence\": \"No timeline discovery directly addresses upstream regulation of EXTL2 or the structural code linking its GAG products to specific receptor outcomes\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Upstream regulators of EXTL2 expression/activity unknown\", \"Unified structural model linking GAG length/composition to receptor selectivity absent\", \"Tissue-specific balance of initiation vs termination not quantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 2, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 5, 10]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 4, 9, 10]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8, 9]}\n    ],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}